NOVAVAX Reports Additional Positive Data From Its Trivalent Seasonal Influenza (VLP) Vaccine Clinical Study In Healthy … (PharmaceuticalOnline)

February 9, 2010 — Jesse

Novavax, Inc. (Nasdaq: NVAX ) announced today new data from a clinical study that began in May of 2009 among healthy adults 18 to 49 years of age with Novavax’s trivalent seasonal influenza Virus-like Particle (VLP) vaccine.

Read the original:
NOVAVAX Reports Additional Positive Data From Its Trivalent Seasonal Influenza (VLP) Vaccine Clinical Study In Healthy … (PharmaceuticalOnline)

Posted in H1N1 Flu, H1N1 News, Influenza Virus. Tags: , , , , , , , , , , , .
«

»